The past 25 years have witnessed immense progress in our understanding of the systemic, tissue-specific, and cellular consequences of severe injury and infection. Despite such insights, considerable controversy remains regarding appropriate biologic and management interventions to prevent or ameliorate the associated adverse outcomes.
Methods:
A review of several scientific developments arising from studies initiated at Cornell University Medical College during the tenure of Dr. G. Tom Shires. The implications of those and subsequent studies are discussed.
Results:
An understanding of patient-specific variation and adaptability could direct individualized biologic and management interventions for severe injury and infection.
Conclusion:
Despite more detailed appreciation of the molecular mechanisms of danger and pathogen recognition and response biology, we have much to learn about the complexity of severe injury and infection. There is a great need to extend our investigation of these mechanisms to experimental and stress-modified clinical scenarios.
Get full access to this article
View all access options for this article.
References
1.
ShiresGT, FisherO, MurphyPet al.Recombinant activated protein C induces dose-dependent changes in inflammatory mediators, tissue damage, and apoptosis in in vivo rat model of sepsis. Surg Infect, 2007; 8:377–386.
2.
ShiresGT. Response to “Delayed fluid resuscitation in hemorrhagic shock induces proinflammatory cytokine response.”Ann Emerg Med, 2007; 50:354.
3.
CarswellEA, OldLJ, KasselRLet al.An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA, 1975; 72:3666–3670.
4.
BeutlerB, GreenwaldD, HulmesJDet al.Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature, 1985; 316:552–554.
HesseDG, TraceyKJ, FongYet al.Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet, 1988; 166:147–153.
9.
MaranoMA, FongY, MoldawerLLet al.Serum cachectin/tumor necrosis factor in critically ill patients with burns correlates with infection and mortality. Surg Gynecol Obstet, 1990; 170:32–38.
10.
BarberAE, CoyleSM, MaranoMAet al.Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol, 1993; 150:1999–2006.
11.
MichieHR, ManogueKR, SpriggsDRet al.Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med, 1988; 318:1481–1486.
12.
van der PollT, CoyleSM, BarbosaKet al.Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. J Clin Invest, 1996; 97:713–719.
13.
DinarelloCA, RoubenoffR. George Clowes' classic paper and the search for “muscle proteolysis factor.”Nutrition, 1996; 12:67–68.
FischerE, MaranoMA, Van ZeeKJet al.Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest, 1992; 89:1551–1557.
16.
van der PollT, CoyleSM, LeviMet al.Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. Blood, 1997; 89:3727–3734.
17.
van der PollT, JansenPM, van ZeeKJet al.Tumor necrosis factor-alpha induces activation of coagulation and fibrinolysis in baboons through an exclusive effect on the p55 receptor. Blood, 1996; 88:922–927.
18.
van ZeeKJ, KohnoT, FischerEet al.Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA, 1992; 89:4845–4859.
19.
van ZeeKJ, MoldawerLL, OldenburgHSet al.Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)–Ig fusion protein, Ro 45-2081. J Immunol, 1996; 156:2221–2230.
20.
OpalSM, CrossAS. Clinical trials for severe sepsis: Past failures, and future hopes. Infect Dis Clin North Am, 1999; 13:285–297.
21.
EichackerPQ, ParentC, KalilAet al.Risk and the efficacy of antiinflammatory agents: Retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med, 2002; 166:1197–1205.
22.
van der PollT, LeviM, DentenerMet al.Epinephrine exerts anticoagulant effects during human endotoxemia. J Exp Med, 1997; 185:1143–1148.
23.
BoermeesterMA, van LeeuwenPA, CoyleSMet al.Interleukin-1 blockade attenuates mediator release and dysregulation of the hemostatic mechanism during human sepsis. Arch Surg, 1995; 130:739–748.
24.
BernardGR, VincentJL, LaterrePFet al.Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med, 2001; 344:699–709.
25.
KalilAC, CoyleSM, UmJYet al.Effects of drotrecogin alfa (activated) in human endotoxemia. Shock, 2004; 21:222–229.
26.
BariePS, HydoLJ, ShouJ, EachempatiSR. Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis. Surg Infect, 2006; 7,Suppl 2:S77–S80.
27.
BariePS, WilliamsMD, McCollamJSet al.Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis. Am J Surg, 2004; 188:212–220.
28.
BoneRC, FisherCJJr, ClemmerTPet al.A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med, 1987; 317:653–658.
29.
AnnaneD, BriegelJ, SprungCL. Corticosteroid insufficiency in acutely ill patients. N Engl J Med, 2003; 348:2157–2159.
30.
SprungCL, AnnaneD, KehDet al.Hydrocortisone therapy for patients with septic shock. N Engl J Med, 2008; 358:111–124.
31.
LowrySF, CalvanoSE. Challenges for modeling and interpreting the complex biology of severe injury and inflammation. J Leukocyte Biol, 2008; 83:553–557.
32.
RixenD, SiegelJH, Abu-SalihAet al.Physiologic state severity classification as an indicator of posttrauma cytokine response. Shock, 1995; 4:27–38.
33.
RixenD, SiegelJH, FriedmanHP. “Sepsis/SIRS,” physiologic classification, severity stratification, relation to cytokine elaboration and outcome prediction in posttrauma critical illness. J Trauma, 1996; 41:581–598.
34.
SiegelJH, VaryTC, RivkindAet al.Abnormal metabolic control in the septic multiple organ failure syndrome: Pharmacotherapy for altered fuel control mechanisms. Prog Clin Biol Res, 1989; 308:535–543.
35.
TschoekeSK, HellmuthM, HostmannAet al.The early second hit in trauma management augments the proinflammatory immune response to multiple injuries. J Trauma, 2007; 62:1396–1403.
36.
ChenCJ, KonoH, GolenbockDet al.Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med, 2007; 13:851–856.
37.
BartonGM. A calculated response: Control of inflammation by the innate immune system. J Clin Invest, 2008; 118:413–420.
38.
NathanC. Points of control in inflammation. Nature, 2002; 420:846–852.
39.
FullerPM, LuJ, SaperCB. Differential rescue of light- and food-entrainable circadian rhythms. Science, 2008; 320:1074–1077.
40.
MartinoTA, OuditGY, HerzenbergAMet al.Circadian rhythm disorganization produces profound cardiovascular and renal disease in hamsters. Am J Physiol Regul Integr Comp Physiol, 2008; 294:R1675–R1683.
41.
KohsakaA, BassJ. A sense of time: How molecular clocks organize metabolism. Trends Endocrinol Metab, 2007; 18:4–11.
42.
CarlsonDE, ChiuWC. The absence of circadian cues during recovery from sepsis modifies pituitary-adrenocortical function and impairs survival. Shock, 2008; 29:127–132.
43.
OkadaK, YanoM, DokiYet al.Injection of LPS causes transient suppression of biological clock genes in rats. J Surg Res, 2008; 145:5–12.
44.
CavadiniG, PetrzilkaS, KohlerPet al.TNF-alpha suppresses the expression of clock genes by interfering with E-box-mediated transcription. Proc Natl Acad Sci USA, 2007; 104:12843–12848.
45.
BonnemeierH, RichardtG, PotratzJet al.Circadian profile of cardiac autonomic nervous modulation in healthy subjects: Differing effects of aging and gender on heart rate variability. J Cardiovasc Electrophysiol, 2003; 14:791–799.
46.
AnnaneD, TraboldF, SharsharTet al.Inappropriate sympathetic activation at onset of septic shock: A spectral analysis approach. Am J Respir Crit Care Med, 1999; 160:458–465.
47.
TraceyKJ. Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest, 2007; 117:289–296.
48.
SteptoeA, WardleJ, MarmotM. Positive affect and health-related neuroendocrine, cardiovascular, and inflammatory processes. Proc Natl Acad Sci USA, 2005; 102:6508–6512.
49.
LowrySF. Host metabolic response to injury. GallinJ, FauciA. Advances in Host Defense Mechanisms. New York: Raven Press, 1986; 169–190.
50.
van den BergheG, de ZegherF, BouillonR. Clinical review 95: Acute and prolonged critical illness as different neuroendocrine paradigms. J Clin Endocrinol Metab, 1998; 83:1827–1834.
51.
AngusDC, Linde-ZwirbleWT, LidickerJet al.Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med, 2001; 29:1303–1310.
52.
DhainautJF, ClaessensYE, JanesJ, NelsonDR. Underlying disorders and their impact on the host response to infection. Clin Infect Dis, 2005; 41,Suppl 7:S481–S489.
53.
GruverAL, HudsonLL, SempowskiGD. Immunosenescence of ageing. J Pathol, 2007; 211:144–156.
54.
OpalSM, GirardTD, ElyEW. The immunopathogenesis of sepsis in elderly patients. Clin Infect Dis, 2005; 41,Suppl 7:S504–S512.
55.
YendeS, TuomanenEI, WunderinkRet al.Preinfection systemic inflammatory markers and risk of hospitalization due to pneumonia. Am J Respir Crit Care Med, 2005; 172:1440–1446.
56.
CesariM, PenninxBW, NewmanABet al.Inflammatory markers and onset of cardiovascular events: Results from the Health ABC study. Circulation, 2003; 108:2317–2322.
57.
KrabbeKS, BruunsgaardH, HansenCMet al.Ageing is associated with a prolonged fever response in human endotoxemia. Clin Diagn Lab Immunol, 2001; 8:333–338.
58.
BruunsgaardH, SkinhojP, QvistJ, PedersenBK. Elderly humans show prolonged in vivo inflammatory activity during pneumococcal infections. J Infect Dis, 1999; 180:551–554.
59.
MagnottiLJ, FischerPE, ZarzaurBLet al.Impact of gender on outcomes after blunt injury: A definitive analysis of more than 36,000 trauma patients. J Am Coll Surg, 2008; 206:984–991.
60.
SperryJL, NathensAB, FrankelHLet al.Characterization of the gender dimorphism after injury and hemorrhagic shock: Are hormonal differences responsible?Crit Care Med, 2008; 36:1838–1845.
61.
SorensenTI, NielsenGG, AndersenPK, TeasdaleTW. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med, 1988; 318:727–732.
62.
WurfelMM, ParkWY, RadellaFet al.Identification of high and low responders to lipopolysaccharide in normal subjects: An unbiased approach to identify modulators of innate immunity. J Immunol, 2005; 175:2570–2578.
63.
de CraenAJ, PosthumaD, RemarqueEJet al.Heritability estimates of innate immunity: An extended twin study. Genes Immun, 2005; 6:167–170.
64.
BuchmanTG. Nonlinear dynamics, complex systems, and the pathobiology of critical illness. Curr Opin Crit Care, 2004; 10:378–382.
65.
MorrisJAJr, NorrisPR, OzdasAet al.Reduced heart rate variability: An indicator of cardiac uncoupling and diminished physiologic reserve in 1,425 trauma patients. J Trauma, 2006; 60:1165–1173.
66.
NorrisPR, MorrisJAJr, OzdasAet al.Heart rate variability predicts trauma patient outcome as early as 12 h: Implications for military and civilian triage. J Surg Res, 2005; 129:122–128.
67.
NorrisPR, OzdasA, CaoHet al.Cardiac uncoupling and heart rate variability stratify ICU patients by mortality: A study of 2088 trauma patients. Ann Surg, 2006; 243:804–812.
68.
GodinPJ, BuchmanTG. Uncoupling of biological oscillators: A complementary hypothesis concerning the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med, 1996; 24:1107–1116.
69.
van den BergheGH. The neuroendocrine stress response and modern intensive care: The concept revisited. Burns, 1999; 25:7–16.
70.
MorrisJAJr, NorrisPR, WaitmanLRet al.Adrenal insufficiency, heart rate variability, and complex biologic systems: A study of 1,871 critically ill trauma patients. J Am Coll Surg, 2007; 204:885–892.
71.
RiversE, NguyenB, HavstadSet al.Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med, 2001; 345:1368–1377.
72.
RiversEP, KruseJA, JacobsenGet al.The influence of early hemodynamic optimization on biomarker patterns of severe sepsis and septic shock. Crit Care Med, 2007; 35:2016–2024.
73.
LangK, BoldtJ, SuttnerS, HaischG. Colloids versus crystalloids and tissue oxygen tension in patients undergoing major abdominal surgery. Anesth Analg, 2001; 93:405–409.
74.
LangK, SuttnerS, BoldtJet al.Volume replacement with HES 130/0.4 may reduce the inflammatory response in patients undergoing major abdominal surgery. Can J Anaesth, 2003; 50:1009–1016.
75.
McKinleyBA, ValdiviaA, MooreFA. Goal-oriented shock resuscitation for major torso trauma: What are we learning?Curr Opin Crit Care, 2003; 9:292–299.
76.
BoldtJ, DuckeM, KumleBet al.Influence of different volume replacement strategies on inflammation and endothelial activation in the elderly undergoing major abdominal surgery. Intensive Care Med, 2004; 30:416–422.
77.
RheeP, HadjizachariaP, TrankiemCet al.What happened to total parenteral nutrition? The disappearance of its use in a trauma intensive care unit. J Trauma, 2007; 63:1215–1222.
78.
FongYM, MaranoMA, BarberAet al.Total parenteral nutrition and bowel rest modify the metabolic response to endotoxin in humans. Ann Surg, 1989; 210:449–456.
79.
LowrySF. The route of feeding influences injury responses. J Trauma, 1990; 30,12 Suppl:S10–S15.
80.
van der PollT, LeviM, BraxtonCCet al.Parenteral nutrition facilitates activation of coagulation but not of fibrinolysis during human endotoxemia. J Infect Dis, 1998; 177:793–795.
81.
van der PollT, CoyleSM, LeviMet al.Fat emulsion infusion potentiates coagulation activation during human endotoxemia. Thromb Haemost, 1996; 75:83–86.
82.
LowrySF. A new model of nutrition influenced inflammatory risk. J Am Coll Surg, 2007; 205,4 Suppl:S65–S68.
